Merck's Pimicotinib Study Targets Tenosynovial Giant Cell Tumor in Japan
A study is underway to evaluate the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese patients with TGCT.
Asset / Drug
Drug and asset intelligence for pimicotinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.